Kappa opioid receptor antagonists are provided that yieldsignificant improvements in functional binding assays to kappaopioid receptors relative to nor-BNI, and the use of theseantagonists in treatment of disease states that are ameliorated bybinding of the kappa opioid receptor such as heroin or cocaineaddictions.
